Avivomed
- Industry
- Medical Devices
- Founded Year
- 2020
- Headquarters
- 2896 Centre Pointe Drive, Roseville, MN 55113, United States
- Employee Count
- 14
Key People
- Dan Brounstein - Chief Executive Officer
- Mudit Jain - Co-Founder and Chairman of the Board
- Stephen Masson - Co-Founder
- Lynn Elliott - Co-Founder
- Paul Mazanec - Chief Technology Officer, Vice President of Research & Development
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with extensive backgrounds in the medical device industry.
The presence of multiple successful MedTech entrepreneurs, including CEO Dan Brounstein and Co-Founder Mudit Jain, enhances the company's potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: Avivomed addresses significant unmet clinical needs in chronic disease treatment through neuromodulation.
The company's focus on developing neuromodulation therapies for chronic diseases targets a substantial patient population with limited existing solutions.
- Competition
-
Aspect: Somewhat crowded
Summary: The neuromodulation market has several established players, presenting moderate competition.
While Avivomed's innovative approach offers differentiation, the presence of multiple competitors in the neuromodulation space poses challenges.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing advanced neuromodulation devices involves moderate technical complexity.
The technical challenges are manageable given the team's expertise, but they require careful execution to ensure device efficacy and safety.
- Patent
-
Aspect: Applied
Summary: Avivomed has pending patents for its neuromodulation technology.
The company's pending patents, such as the 'Cranial nerve stimulator with therapeutic feedback,' indicate a commitment to protecting its innovations.
- Financing
-
Aspect: Well-funded
Summary: Avivomed has secured significant funding, including a $32 million Series A round.
The substantial funding from reputable investors provides a solid financial foundation for product development and commercialization efforts.
- Regulatory
-
Aspect: Running FIH
Summary: The company is in the early stages of clinical trials for its neuromodulation devices.
Initiating first-in-human trials is a critical step toward regulatory approval, demonstrating progress in the development pipeline.
Opportunity Rollup
- Odds of Success
- 3.9
- Peak Market Share
- 4.8
- Segment CAGR
- 4.9%
- Market Segment
- Neuromodulation Devices
- Market Sub Segment
- Chronic Disease Treatment
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.72 |
| 3 | 1.68 |
| 4 | 3.36 |
| 5 | 4.80 |
Key Takeaway
Avivomed's experienced team and strong financial backing position it well to address significant unmet needs in chronic disease treatment through innovative neuromodulation therapies.